AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

In a new lawsuit, AbbVie’s Pharmacyclics unit contends BeiGene’s Brukinsa infringes a patent on its blood cancer drug Imbruvica. Both Imbruvica and Brukinsa are irreversible BTK inhibitors approved in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).